跳至主要内容
临床试验/KCT0008274
KCT0008274进行中(未招募)Unknown

To evaluate the safety and efficacy of hyperbaric oxygen therapy(by IO-HBOT-DL600-2400-ACNT-1) as a treatment for fatigue symptoms of post-COVID condition, explorative, non-randomized, open-label, single-arm, single center, Investigator-initiated Trial

Myongji Hospital0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
进行中(未招募)
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20(Year) 至 69(Year)(—)
性别
All

入选标准

  • 1) Subjects who have passed more than 12 weeks from the date of diagnosis of COVID-19 infection by RT-PCR or expert rapid antigen test
  • 2) Subjects whose fatigue symptoms newly occurred within 6 months after COVID-19 was confirmed and continues to this day, and who scored 4 or more on the Chalder Fatigue scale (CFS)
  • 3) Adults aged 20 to 69 years old
  • 4) ECOG (Eastern Cooperative Oncology Group) PS of 0 or 1
  • 5) Subjects (or legal representatives) agree to participate before clinical trial begins and provide informed written consent
  • 6) Those who can read Korean

排除标准

  • 1) Brain disease: Subjects with brain disease including dementia, stroke, epilepsy, and head trauma with loss of consciousness
  • 2) Cardiac disease: Subjects with ischemic heart disease, heart failure, uncontrolled symptomatic arrhythmias, or those who have suggestive findings with the relevant disease based on electrocardiogram (ECG) and chest x-ray examination performed before clinical trials
  • 3) Lung disease: Subjects with a history of chronic obstructive pulmonary disease (COPD), emphysema, asthma, pneumothorax, or chest surgery, and those with findings suggesting the corresponding disease on chest x-ray or before clinical trials.
  • 4) Upper respiratory infection: Subjects with symptoms suggesting upper respiratory infection, such as fever of 38 degrees or higher, cough, sore throat, nasal congestion, runny nose, etc. at the time of participating in hyperbaric oxygen therapy.
  • 5) Otology disease: Subjects who may have problems with ear pressure control, such as otitis media, severe rhinitis, and a history of barotrauma
  • 6) Cancer (malignant tumor): Subjects with a history of malignant disease that is currently ongoing or has required active treatment within the past year. Participation in the study is possible if the subject has been in a stable condition without disease recurrence for more 1 year after complete cure.
  • Note: Subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., ductal carcinoma in situ and cervical carcinoma in situ) who have received potentially curative treatment are not excluded if treatment is completed within 6 months.
  • 7) Subjects who are confirmed to be alcohol or drug dependent within 4 weeks before participation in the study
  • 8) Subjects who have been diagnosed with schizophrenia or has a mental illness that cannot be controlled at the opinion of investigator
  • 9) Subjects who cannot receive hyperbaric oxygen therapy due to claustrophobia
  • 10) Subjects with a diagnosis of immunodeficiency or receiving long-term systemic steroid treatment (dose exceeding the equivalent of 10 mg of prednisone per day) or subjects who have received any form of other immunosuppressive treatment within 7 days prior to clinical trial treatment
  • Note: If it is undergoing a reduction in steroid for discontinuation during the screening period, they are not excluded from the study.
  • 11) Women who are currently pregnant
  • 12) The subject is currently participating in a trial for clinical investigational medical devices, or clinical investigational drugs or medical devices within 4 weeks prior to participating in this study
  • 13) Subjects who have received hyperbaric oxygen therapy after diagnosed COVID-19
  • 14) Subject has had major surgery within 2 weeks before participating in the clinical trial or did not recover from any effects of major surgery
  • 15) Subject is unlikely to comply with the study procedures and limitations and requirements of the study in the opinion of the investigator

研究者

相似试验

Clinical trial evaluating the safety and efficacy of... | 临床试验